Home/Pipeline/ALN-KHK

ALN-KHK

Type 2 Diabetes

Phase 1Active

Key Facts

Indication

Type 2 Diabetes

Phase

Phase 1

Status

Active

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.

View full company profile

Therapeutic Areas

Rare Genetic Diseases Cardio-Metabolic Diseases Hepatic Infectious Diseases Central Nervous System (CNS) Diseases Ocular Diseases

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
Metformin API	USV Biologics Division	Commercial	Active
Empagliflozin	Azico Biophore	Commercial	Active
Sitagliptin Intermediate	AR Life Science	Commercial	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Sitagliptin Phosphate Polymorph	Morepen Laboratories	Pre‑clinical	Active
Hepatic Denervation for Type 2 Diabetes	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active